NASDAQ : ALNY
Alnylam Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 165 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 22.10B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 22.10B |
| Enterprise Value | 21.51B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 133.94M |
| Shares Outstanding | 133.94M |
| Shares Change (YoY) | +3.63% |
| Shares Change (QoQ) | -0.17% |
| Owned by Insiders (%) | 0.19% |
| Owned by Institutions (%) | 100.70% |
| Float | 133.63M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 8.55 |
| Forward PE | 22.33 |
| PS Ratio | 4.41 |
| Forward PS | 3.37 |
| PB Ratio | 6.13 |
| P/TBV Ratio | 6.13 |
| P/FCF Ratio | 27.41 |
| P/OCF Ratio | 23.12 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 8.12 |
| EV / Sales | 4.29 |
| EV / EBITDA | 20.82 |
| EV / EBIT | 22.00 |
| EV / FCF | 26.68 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.48 |
| Quick Ratio | 2.26 |
| Debt / Equity | 0.83 |
| Debt / EBITDA | 2.69 |
| Debt / FCF | 3.72 |
| Interest Coverage | 3.25 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 138.07% |
| Return on Assets (ROA) | 9.51% |
| Return on Invested Capital (ROIC) | 48.31% |
| Return on Capital Employed (ROCE) | 16.48% |
| Weighted Average Cost of Capital (WACC) | 6.00% |
| Revenue Per Employee | $2.01M |
| Profits Per Employee | $1.06M |
| Employee Count | 2,500 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 12.57 |
Taxes
| Measure | Value |
|---|
| Income Tax | -1.87B |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.27 |
| 52-Week Price Change | -65.74% |
| 50-Day Moving Average | 236.50 |
| 200-Day Moving Average | 285.48 |
| Relative Strength Index (RSI) | 22.05 |
| Average Volume (20 Days) | 2,168,936 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.57M |
| Short Previous Month | 7.71M |
| Short % of Shares Out | 4.90% |
| Short % of Float | 4.92% |
| Short Ratio (days to cover) | 5.02 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 5.01B |
| Gross Profit | 3.87B |
| Operating Income | 977.59M |
| Pretax Income | 781.53M |
| Net Income | 2.65B |
| EBITDA | 1.03B |
| EBIT | 977.59M |
| Earnings Per Share (EPS) | $19.29 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.59B |
| Total Debt | 3.00B |
| Net Cash | 590.40M |
| Net Cash Per Share | $4.41 |
| Equity (Book Value) | 3.60B |
| Book Value Per Share | 26.92 |
| Working Capital | 3.05B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 955.94M |
| Capital Expenditures | -149.64M |
| Depreciation & Amortization | 55.43M |
| Net Borrowing | -52.93M |
| Free Cash Flow | 806.31M |
| FCF Per Share | $6.02 |
Margins
| Measure | Value |
|---|
| Gross Margin | 77.28% |
| Operating Margin | 19.50% |
| Pretax Margin | 15.59% |
| Profit Margin | 52.85% |
| EBITDA Margin | 20.61% |
| EBIT Margin | 19.50% |
| FCF Margin | 16.08% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.63% |
| Shareholder Yield | -3.63% |
| Earnings Yield | 11.69% |
| FCF Yield | 3.65% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $310.89 |
| Price Target Difference | 88.42% |
| Analyst Consensus | Buy |
| Analyst Count | 30 |
| Revenue Growth Forecast (3Y) | 28.23% |
| EPS Growth Forecast (3Y) | 38.37% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 6.83 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |